Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 201

1.

Reoperations After Bariatric Surgery in 26 Years of Follow-up of the Swedish Obese Subjects Study.

Hjorth S, Näslund I, Andersson-Assarsson JC, Svensson PA, Jacobson P, Peltonen M, Carlsson LMS.

JAMA Surg. 2019 Jan 2. doi: 10.1001/jamasurg.2018.5084. [Epub ahead of print]

PMID:
30601881
2.

Dose-Response-Time Data Analysis: An Underexploited Trinity.

Gabrielsson J, Andersson R, Jirstrand M, Hjorth S.

Pharmacol Rev. 2019 Jan;71(1):89-122. doi: 10.1124/pr.118.015750. Review.

PMID:
30587536
3.

The aromatic amino acid sensor GPR142 controls metabolism through balanced regulation of pancreatic and gut hormones.

Rudenko O, Shang J, Munk A, Ekberg JP, Petersen N, Engelstoft MS, Egerod KL, Hjorth SA, Wu M, Feng Y, Zhou YP, Mokrosinski J, Thams P, Reimann F, Gribble F, Rehfeld JF, Holst JJ, Treebak JT, Howard AD, Schwartz TW.

Mol Metab. 2019 Jan;19:49-64. doi: 10.1016/j.molmet.2018.10.012. Epub 2018 Nov 5.

4.

Lost in translation: What's in an EC50? Innovative PK/PD reasoning in the drug development context.

Gabrielsson J, Peletier LA, Hjorth S.

Eur J Pharmacol. 2018 Sep 15;835:154-161. doi: 10.1016/j.ejphar.2018.07.037. Epub 2018 Jul 21.

PMID:
30036536
5.

Leishmaniasis.

Knudsen DK, Kofoed K, Hjorth SV.

Ugeskr Laeger. 2018 Jul 9;180(28). pii: V69596. Danish. No abstract available.

PMID:
29984701
6.

Long-term incidence of serious fall-related injuries after bariatric surgery in Swedish obese subjects.

Carlsson LMS, Sjöholm K, Ahlin S, Jacobson P, Andersson-Assarsson JC, Karlsson Lindahl L, Maglio C, Karlsson C, Hjorth S, Taube M, Carlsson B, Svensson PA, Peltonen M.

Int J Obes (Lond). 2018 May 24. doi: 10.1038/s41366-018-0097-y. [Epub ahead of print]

7.

[Multicentric reticulohistiocytosis is a rare form of paraneoplasia].

Anderson AM, Todberg T, Kofoed K, Iversen TZ, Andersen M, Hjorth SV, Fassi DE.

Ugeskr Laeger. 2018 Jan 1;180(1). pii: V08170611. Danish.

PMID:
29298742
8.

Receptor structure-based discovery of non-metabolite agonists for the succinate receptor GPR91.

Trauelsen M, Rexen Ulven E, Hjorth SA, Brvar M, Monaco C, Frimurer TM, Schwartz TW.

Mol Metab. 2017 Dec;6(12):1585-1596. doi: 10.1016/j.molmet.2017.09.005. Epub 2017 Sep 30.

9.

In vivo potency revisited - Keep the target in sight.

Gabrielsson J, Peletier LA, Hjorth S.

Pharmacol Ther. 2018 Apr;184:177-188. doi: 10.1016/j.pharmthera.2017.10.011. Epub 2017 Oct 10. Review.

PMID:
29024741
10.

GPCR-Mediated Signaling of Metabolites.

Husted AS, Trauelsen M, Rudenko O, Hjorth SA, Schwartz TW.

Cell Metab. 2017 Apr 4;25(4):777-796. doi: 10.1016/j.cmet.2017.03.008. Review.

11.

Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post-hoc analysis of participants from the Swedish Obese Subjects study.

Carlsson LMS, Sjöholm K, Karlsson C, Jacobson P, Andersson-Assarsson JC, Svensson PA, Larsson I, Hjorth S, Neovius M, Taube M, Carlsson B, Peltonen M.

Lancet Diabetes Endocrinol. 2017 Apr;5(4):271-279. doi: 10.1016/S2213-8587(17)30061-X. Epub 2017 Feb 23.

12.

Weight Perturbation Alters Leptin Signal Transduction in a Region-Specific Manner throughout the Brain.

Morabito MV, Ravussin Y, Mueller BR, Skowronski AA, Watanabe K, Foo KS, Lee SX, Lehmann A, Hjorth S, Zeltser LM, LeDuc CA, Leibel RL.

PLoS One. 2017 Jan 20;12(1):e0168226. doi: 10.1371/journal.pone.0168226. eCollection 2017.

13.

Deletion of Gpr55 Results in Subtle Effects on Energy Metabolism, Motor Activity and Thermal Pain Sensation.

Bjursell M, Ryberg E, Wu T, Greasley PJ, Bohlooly-Y M, Hjorth S.

PLoS One. 2016 Dec 12;11(12):e0167965. doi: 10.1371/journal.pone.0167965. eCollection 2016.

14.
15.

Pattern Recognition in Pharmacodynamic Data Analysis.

Gabrielsson J, Hjorth S.

AAPS J. 2016 Jan;18(1):64-91. doi: 10.1208/s12248-015-9842-5. Epub 2015 Nov 5. Review.

PMID:
26542613
16.

Pharmacological profiling of the hemodynamic effects of cannabinoid ligands: a combined in vitro and in vivo approach.

Walsh SK, Hepburn CY, Keown O, Åstrand A, Lindblom A, Ryberg E, Hjorth S, Leslie SJ, Greasley PJ, Wainwright CL.

Pharmacol Res Perspect. 2015 Jun;3(3):e00143. doi: 10.1002/prp2.143. Epub 2015 May 8.

17.

A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates.

Hjorth S, Karlsson C, Jucaite A, Varnäs K, Wählby Hamrén U, Johnström P, Gulyás B, Donohue SR, Pike VW, Halldin C, Farde L.

Neuropharmacology. 2016 Feb;101:519-30. doi: 10.1016/j.neuropharm.2015.03.002. Epub 2015 Mar 17.

18.

Cutting Edge: identification of neutrophil PGLYRP1 as a ligand for TREM-1.

Read CB, Kuijper JL, Hjorth SA, Heipel MD, Tang X, Fleetwood AJ, Dantzler JL, Grell SN, Kastrup J, Wang C, Brandt CS, Hansen AJ, Wagtmann NR, Xu W, Stennicke VW.

J Immunol. 2015 Feb 15;194(4):1417-21. doi: 10.4049/jimmunol.1402303. Epub 2015 Jan 16.

19.

Baseline anandamide levels and body weight impact the weight loss effect of CB1 receptor antagonism in male rats.

Karlsson C, Hjorth S, Karpefors M, Hansson GI, Carlsson B.

Endocrinology. 2015 Apr;156(4):1237-41. doi: 10.1210/en.2014-1730. Epub 2014 Dec 30.

20.

Modeling and design of challenge tests: Inflammatory and metabolic biomarker study examples.

Gabrielsson J, Hjorth S, Vogg B, Harlfinger S, Gutierrez PM, Peletier L, Pehrson R, Davidsson P.

Eur J Pharm Sci. 2015 Jan 25;67:144-159. doi: 10.1016/j.ejps.2014.11.006. Epub 2014 Nov 28.

PMID:
25435491
21.

Modeling energy intake by adding homeostatic feedback and drug intervention.

Gennemark P, Hjorth S, Gabrielsson J.

J Pharmacokinet Pharmacodyn. 2015 Feb;42(1):79-96. doi: 10.1007/s10928-014-9399-4. Epub 2014 Nov 12.

PMID:
25388764
22.

Effects of a novel MC4R agonist on maintenance of reduced body weight in diet-induced obese mice.

Skowronski AA, Morabito MV, Mueller BR, Lee S, Hjorth S, Lehmann A, Watanabe K, Zeltser LM, Ravussin Y, Rosenbaum M, LeDuc CA, Leibel RL.

Obesity (Silver Spring). 2014 May;22(5):1287-95. doi: 10.1002/oby.20678. Epub 2014 Jan 9.

23.

Significance of acquired diverticular disease of the vermiform appendix: a marker of regional neoplasms?

Kallenbach K, Hjorth SV, Engel U, Schlesinger NH, Holck S.

J Clin Pathol. 2012 Jul;65(7):638-42. doi: 10.1136/jclinpath-2011-200647. Epub 2012 Mar 29.

PMID:
22461655
24.

Crystal structure of interleukin-21 receptor (IL-21R) bound to IL-21 reveals that sugar chain interacting with WSXWS motif is integral part of IL-21R.

Hamming OJ, Kang L, Svensson A, Karlsen JL, Rahbek-Nielsen H, Paludan SR, Hjorth SA, Bondensgaard K, Hartmann R.

J Biol Chem. 2012 Mar 16;287(12):9454-60. doi: 10.1074/jbc.M111.311084. Epub 2012 Jan 10.

25.

Binding properties of antagonists to cannabinoid receptors in intact cells.

Wennerberg M, Cheng L, Hjorth S, Clapham JC, Balendran A, Vauquelin G.

Fundam Clin Pharmacol. 2011 Apr;25(2):200-10. doi: 10.1111/j.1472-8206.2010.00843.x.

PMID:
20608998
26.

Acute lymphoblastic leukemia with Philadelphia chromosome in a 39-year-old woman with Down syndrome presenting as meningitis and fulminant liver failure.

Hjorth SV, Vainer B, Petersen BL, Larsen FS, Hasle H.

Leuk Res. 2010 Nov;34(11):e297-9. doi: 10.1016/j.leukres.2010.06.007. Epub 2010 Jul 3. No abstract available.

PMID:
20598743
27.

Rational design of interleukin-21 antagonist through selective elimination of the gammaC binding epitope.

Kang L, Bondensgaard K, Li T, Hartmann R, Hjorth SA.

J Biol Chem. 2010 Apr 16;285(16):12223-31. doi: 10.1074/jbc.M110.101444. Epub 2010 Feb 18.

28.

Novel thioamide derivatives as neutral CB1 receptor antagonists.

Boström J, Olsson RI, Tholander J, Greasley PJ, Ryberg E, Nordberg H, Hjorth S, Cheng L.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):479-82. doi: 10.1016/j.bmcl.2009.11.125. Epub 2009 Nov 27.

PMID:
20005704
30.

The orphan receptor GPR55 is a novel cannabinoid receptor.

Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ.

Br J Pharmacol. 2007 Dec;152(7):1092-101. Epub 2007 Sep 17.

31.

The existence of multiple conformers of interleukin-21 directs engineering of a superpotent analogue.

Bondensgaard K, Breinholt J, Madsen D, Omkvist DH, Kang L, Worsaae A, Becker P, Schiødt CB, Hjorth SA.

J Biol Chem. 2007 Aug 10;282(32):23326-36. Epub 2007 Jun 12.

32.

Sequence-based typing of Mycoplasma genitalium reveals sexual transmission.

Hjorth SV, Björnelius E, Lidbrink P, Falk L, Dohn B, Berthelsen L, Ma L, Martin DH, Jensen JS.

J Clin Microbiol. 2006 Jun;44(6):2078-83.

33.

Phenotypic and genotypic characterization of prolyliminopeptidase-negative Neisseria gonorrhoeae isolates in Denmark.

Fjeldsøe-Nielsen H, Unemo M, Fredlund H, Hjorth SV, Berthelsen LM, Palmer HM, Friis-Møller A.

Eur J Clin Microbiol Infect Dis. 2005 Apr;24(4):280-3. Erratum in: Eur J Clin Microbiol Infect Dis. 2005 Jul;24(7):503.

PMID:
15902536
34.

Identification and characterisation of a novel splice variant of the human CB1 receptor.

Ryberg E, Vu HK, Larsson N, Groblewski T, Hjorth S, Elebring T, Sjögren S, Greasley PJ.

FEBS Lett. 2005 Jan 3;579(1):259-64.

35.

Osteoporosis in MCHR1-deficient mice.

Bohlooly-Y M, Mahlapuu M, Andersén H, Astrand A, Hjorth S, Svensson L, Törnell J, Snaith MR, Morgan DG, Ohlsson C.

Biochem Biophys Res Commun. 2004 Jun 11;318(4):964-9.

PMID:
15147966
36.
37.

Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex.

Felton TM, Kang TB, Hjorth S, Auerbach SB.

Naunyn Schmiedebergs Arch Pharmacol. 2003 Mar;367(3):297-305. Epub 2003 Feb 4.

PMID:
12644903
38.

Scale-up of stirring as foam disruption (SAFD) to industrial scale.

Hoeks FW, Boon LA, Studer F, Wolff MO, van der Schot F, Vrabél P, van der Lans RG, Bujalski W, Manelius A, Blomsten G, Hjorth S, Prada G, Luyben KCh, Nienow AW.

J Ind Microbiol Biotechnol. 2003 Feb;30(2):118-28. Epub 2003 Feb 8.

PMID:
12612787
39.

Effects on drug disposition, brain monoamines and behavior after chronic treatment with the antidepressant venlafaxine in rats with experimental hepatic encephalopathy.

Wikell C, Apelqvist G, Hjorth S, Kullingsjö J, Bergqvist PB, Bengtsson F.

Eur Neuropsychopharmacol. 2002 Aug;12(4):327-36.

PMID:
12126872
40.

Interaction of a non-peptide agonist with angiotensin II AT1 receptor mutants.

Costa-Neto CM, Miyakawa AA, Pesquero JB, Oliveira L, Hjorth SA, Schwartz TW, Paiva AC.

Can J Physiol Pharmacol. 2002 May;80(5):413-7. Erratum in: Can J Physiol Pharmacol. 2003 Nov;81(11):1083.

PMID:
12056547
41.

Effect of halving the dose of venlafaxine to adjust for putative pharmacokinetic and pharmacodynamic changes in an animal model of chronic hepatic encephalopathy.

Wikell C, Kugelberg FC, Hjorth S, Apelqvist G, Bengtsson F.

Clin Neuropharmacol. 2001 Nov-Dec;24(6):324-33.

PMID:
11801807
42.

Dynamic and kinetic effects of chronic citalopram treatment in experimental hepatic encephalopathy.

Apelqvist G, Wikell C, Carlsson B, Hjorth S, Bergqvist PB, Ahlner J, Bengtsson F.

Clin Neuropharmacol. 2000 Nov-Dec;23(6):304-17.

PMID:
11575864
43.

Sustained administration of the antidepressant venlafaxine in rats: pharmacokinetic and pharmacodynamic findings.

Wikell C, Hjorth S, Apelqvist G, Kullingsjö J, Lundmark J, Bergqvist PB, Bengtsson F.

Naunyn Schmiedebergs Arch Pharmacol. 2001 Apr;363(4):448-55.

PMID:
11330339
44.

Interaction of the antidepressant mirtazapine with alpha2-adrenoceptors modulating the release of 5-HT in different rat brain regions in vivo.

Bengtsson HJ, Kele J, Johansson J, Hjorth S.

Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):406-12.

PMID:
11111835
45.

Constitutive activation of tethered-peptide/corticotropin-releasing factor receptor chimeras.

Nielsen SM, Nielsen LZ, Hjorth SA, Perrin MH, Vale WW.

Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10277-81.

46.

Mutational analysis of the interaction of the N- and C-terminal ends of angiotensin II with the rat AT(1A) receptor.

Costa-Neto CM, Miyakawa AA, Oliveira L, Hjorth SA, Schwartz TW, Paiva AC.

Br J Pharmacol. 2000 Jul;130(6):1263-8.

47.

Serotonin autoreceptor function and antidepressant drug action.

Hjorth S, Bengtsson HJ, Kullberg A, Carlzon D, Peilot H, Auerbach SB.

J Psychopharmacol. 2000 Jun;14(2):177-85. Review.

PMID:
10890313
49.

Pharmacokinetic and pharmacodynamic responses to chronic administration of the selective serotonin reuptake inhibitor citalopram in rats.

Wikell C, Apelqvist G, Carlsson B, Hjorth S, Bergqvist PB, Kugelberg FC, Ahlner J, Bengtsson F.

Clin Neuropharmacol. 1999 Nov-Dec;22(6):327-36.

PMID:
10626092
50.

Autoreceptors remain functional after prolonged treatment with a serotonin reuptake inhibitor.

Hjorth S, Auerbach SB.

Brain Res. 1999 Jul 24;835(2):224-8.

PMID:
10415377

Supplemental Content

Loading ...
Support Center